-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BZolRI9Gh1hsZvDGV/qNEj7SeRZrIPrjdUjnfMGoswGHLz+ZoVe4y6zIPhM8Kgu1 ULY5iUQA/JaGvttNnkJBvQ== 0001204391-07-000017.txt : 20070103 0001204391-07-000017.hdr.sgml : 20070101 20070103202103 ACCESSION NUMBER: 0001204391-07-000017 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061229 FILED AS OF DATE: 20070103 DATE AS OF CHANGE: 20070103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ECKERT R ANDREW CENTRAL INDEX KEY: 0001210525 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-27406 FILM NUMBER: 07506810 MAIL ADDRESS: STREET 1: 3290 WEST BAYSHORE RD CITY: PALO ALTO STATE: CA ZIP: 94303 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CONNETICS CORP CENTRAL INDEX KEY: 0001004960 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943173928 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3400 W BAYSHORE RD CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: 4158432800 MAIL ADDRESS: STREET 1: 3400 W BAYSHORE RD CITY: PALO ALTO STATE: CA ZIP: 94303 FORMER COMPANY: FORMER CONFORMED NAME: CONNECTIVE THERAPEUTICS INC DATE OF NAME CHANGE: 19951214 4 1 edgar.xml PRIMARY DOCUMENT X0202 4 2006-12-29 1 0001004960 CONNETICS CORP CNCT 0001210525 ECKERT R ANDREW 3160 PORTER DRIVE PALO ALTO CA 94304 1 0 0 0 Common Stock, Par Value $0.001 2006-12-29 4 D 0 1111 17.50 D 0 D Common Stock, Par Value $0.001 2006-12-29 4 D 0 7500 17.50 D 0 D Option to Purchase Common Stock 11.60 2006-12-29 4 D 0 30000 5.90 D 2006-12-29 2012-12-12 Common Stock 30000 0 D In connection with the merger agreement between issuer and Stiefel Laboratories, shares of the Issuer's common stock were converted into the right to receive $17.50 per share in cash, without interest. Immediately prior to the effective time of the merger between issuer and Stiefel Laboratories, Inc., all restrictions on these shares of restricted stock were released, and the shares became fully vested and eligible for the merger consideration in an amount equal to $17.50 multiplied by the number of shares of common stock subject to the restrictions, less any required witholding. Immediately prior to the effective time of the merger between issuer and Stiefel Laboratories, the options became fully vested. In exchange for the options, the Issuer paid to the Reporting Person either (a) -0- for each grant of options if the exercise price of the options was equal to or greater than the merger consideration of $17.50, or (b) an amount equal to the excess of the merger consideration ($17.50) over the exercise price multiplied by the number of shares of common stock subject to the option, less any required witholding, if the exercise price of the option was less than the merger consideration of $17.50. The stock options were granted under a Connetics Corporation stock optin plan and, but for the merger between Issuer and Stiefel Laboratories, would have been exercisable at the rate of 25% on the anniversary of the date of the grant over the next 4 years. Katrina J. Church, Attorney-in-Fact for R. Andrew Eckert 2007-01-03 -----END PRIVACY-ENHANCED MESSAGE-----